Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84 ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.

(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs).

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Following Pfizer’s proposed move for Seagen, Ben Hargreaves tracked how the ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...